Agustín Mayo Iscar-rekin lankidetzan egindako argitalpenak (3)

2017

  1. Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin [Oncotarget, 6, (2015), (18875-18890)]. doi: 10.18632/oncotarget.4303

    Oncotarget

2015

  1. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget, Vol. 6, Núm. 22, pp. 18875-18890

2002

  1. The need for continuous immunosuppression with cyclosporin A to maintain an experimental model of uveal melanoma

    Melanoma Research, Vol. 12, Núm. 5, pp. 441-447